GEO DataSets

Analysis of HCT116 colon cancer cells treated with the CDK inhibitor R547 at 3 doses for up to 24 hours. R547 exerts an antiproliferative effect on various cell lines. Results compared with those from PBMCs (GDS5266) and DU145 cells (GDS5267) to identify pharmacodynamic biomarkers for R547.

Organism:

Homo sapiens

Type:

Expression profiling by array, count, 3 agent, 4 dose, 6 time sets

Platform:

GPL570

Series:

GSE15395

74 Samples

Download data: CEL

(Submitter supplied) This SuperSeries is composed of the SubSeries listed below.

Organism:

Homo sapiens

Type:

Expression profiling by array

Platform:

GPL570

156 Samples

Download data: CEL

(Submitter supplied) A genomics-based approach to identify pharmacodynamic biomarkers was used for a CDK (cyclin-dependent kinase) inhibitory drug. R547 is a potent CDK inhibitor with a potent anti-proliferative effect at pharmacologically relevant doses, and is currently in Phase I clinical trials. Utilizing preclinical data derived from microarray experiments, we identified pharmacodynamic biomarkers to test in blood samples from patients in clinical trials. more...

Organism:

Homo sapiens

Type:

Expression profiling by array

Dataset:

GDS5268

Platform:

GPL570

74 Samples

Download data: CEL

(Submitter supplied) A genomics-based approach to identify pharmacodynamic biomarkers was used for a CDK (cyclin-dependent kinase) inhibitory drug. R547 is a potent CDK inhibitor with a potent anti-proliferative effect at pharmacologically relevant doses, and is currently in Phase I clinical trials. Utilizing preclinical data derived from microarray experiments, we identified pharmacodynamic biomarkers to test in blood samples from patients in clinical trials. more...

Organism:

Homo sapiens

Type:

Expression profiling by array

Dataset:

GDS5267

Platform:

GPL570

45 Samples

Download data: CEL

(Submitter supplied) A genomics-based approach to identify pharmacodynamic biomarkers was used for a CDK (cyclin-dependent kinase) inhibitory drug. R547 is a potent CDK inhibitor with a potent anti-proliferative effect at pharmacologically relevant doses, and is currently in Phase I clinical trials. Utilizing preclinical data derived from microarray experiments, we identified pharmacodynamic biomarkers to test in blood samples from patients in clinical trials. more...

Organism:

Homo sapiens

Type:

Expression profiling by array

Dataset:

GDS5266

Platform:

GPL570

37 Samples

Download data: CEL

Analysis of DU145 prostate cancer cells treated with the CDK inhibitor R547 at 3 doses for up to 24 hours. R547 exerts an antiproliferative effect on various cell lines. Results compared with those from PBMCs (GDS5266) and HCT116 cells (GDS5268) to identify pharmacodynamic biomarkers for R547.

Organism:

Homo sapiens

Type:

Expression profiling by array, count, 3 agent, 4 dose, 4 time sets

Platform:

GPL570

Series:

GSE15392

45 Samples

Download data: CEL

Analysis of peripheral blood mononuclear cells treated with CDK inhibitor R547 at 2 doses for 2 and 24 hours. R547 exerts an antiproliferative effect on various cell lines. Results compared with those from DU145 (GDS5267) and HCT116 cells (GDS5268) to identify pharmacodynamic biomarkers for R547.

Organism:

Homo sapiens

Type:

Expression profiling by array, count, 3 agent, 3 dose, 3 time sets

Platform:

GPL570

Series:

GSE15389

37 Samples

Download data: CEL

(Submitter supplied) Microarray analysis of transcriptional changes in biopsies of solid tumors from patients treated in a Phase I study with the Cdk inhibitor PHA-793887.

Organism:

Homo sapiens

Type:

Expression profiling by array

Platform:

GPL6480

7 Samples

Download data: TXT

(Submitter supplied) To identify genes that are modulated by BET inhibitors in blood, we determined global gene expression changes in ABBV-075-treated mouse whole blood samples

Organism:

Mus musculus

Type:

Expression profiling by array

Platform:

GPL1261

15 Samples

Download data: CEL

(Submitter supplied) Determination of transcriptional alterations in skin samples from ABBV-075 treated mice

Organism:

Mus musculus

Type:

Expression profiling by array

Platform:

GPL1261

11 Samples

Download data: CEL

(Submitter supplied) To identify genes that are modulated by BET inhibitors in blood, we determined global gene expression changes in ABBV-075-treated human PBMC samples

Organism:

Homo sapiens

Type:

Expression profiling by array

Platform:

GPL571

10 Samples

Download data: CEL

(Submitter supplied) Competitive inhibitors of acetyl-lysine binding to the bromodomains of the BET (bromodomain and extra terminal) family are being developed for the treatment of solid and heme malignancies. BET family member BRD4 function at enhancers/super-enhancers has been shown to sustain signal-dependent or pathogenic gene expression programs.

Organism:

Homo sapiens

Type:

Expression profiling by array

Platform:

GPL571

36 Samples

Download data: CEL

(Submitter supplied) Competitive inhibitors of acetyl-lysine binding to the bromodomains of the BET (bromodomain and extra terminal) family are being developed for the treatment of solid and heme malignancies. BET family member BRD4 function at enhancers/super-enhancers has been shown to sustain signal-dependent or pathogenic gene expression programs. Here we tested the hypothesis that the transcription factor drivers of castration-resistant prostate cancer (CRPC) clinical progression, including the Androgen Receptor (AR), are critically dependent on BRD4 and thus represent a sensitive solid tumor indication for the BET inhibitor ABBV-075. more...

Organism:

Homo sapiens

Type:

Expression profiling by array

Platform:

GPL570

8 Samples

Download data: CEL